PharmaShots | Incisive News in 3 Shots

Subscribe Now

Braeburn

Braeburn Reports the US Commercial Availability of Brixadi (buprenorphine) Extended-Release Injection for Moderate to Severe Opioid Use Disorder

Braeburn Reports the US Commercial Availability of Brixadi (buprenorphine) Extended-Release Injection for Moderate to Severe Opioi...

September 6, 2023

Braeburn's Brixadi (buprenorphine) Receives the US FDA’s Approval for Moderate to Severe Opioid Use Disorder

Braeburn's Brixadi (buprenorphine) Receives the US FDA’s Approval for Moderate to Severe Opioid Use Disorder

May 23, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us